RIVANNA http://rivannamedical.com, developers of imaging-based medical solutions have announced a $11.6 million contract received from the Biomedical Advanced Research and Development Authority (BARDA) https://phe.gov/about/barda/Pages/default.aspx. The goal is to develop the Accuro® XV geared to the U.S market entry.
BARDA, a Division within the Office of the Assistant Secretary for Preparedness and Response (ASPR) within HHS, awarded the design and development of the computer-aided 3D fracture detection and diagnosis product called Accuro XV for $11.6 million over 24 months with options for additional funding up to $65 million to support further development.
The Accuro XV device is intended for rapid radiation-free bedside fracture triage. If development is successful, the device may help reduce bottlenecks in routine care and mass casually blast trauma incidents by quickly providing a detailed digital visualization of an injury site and then determine whether a facture is present. This approach may enable EDs to fast track care for the large number of low severity simple fractures and sprains.
If there are any Chemical, Biological, Radiological, or Nuclear(CBRN) incidents, easily deployable triage tools are needed to help save lives and to enable a rapid response. Since overwhelming numbers of trauma patients are anticipated in the immediate aftermath of a CBRN incident, it is important to conserve x-ray resources for the highest priority patients.
Accuro XV’s cart based device is designed to be portable, so the device can be deployed in multiple environments. The Accuro XV platform is also being designed with advanced features such as algorithms for AI integration for automated detection of fracture to provide guidance.